The transition goes into effect on Sept. 30, 2025, Chadwick intends to become a senior advisor to Insulet to ensure a smooth transition.
“I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of significant growth,” said Ashley McEvoy, Insulet president and CEO. “She has been instrumental in strengthening our financial foundation and positioning us for continued success.”
Chadwick spent about 18 months in the CFO position at Insulet after taking over in March 2024. Earlier this month, she spoke with optimism about the company’s future plans at the Wells Fargo Conference.
“It has been a privilege to help advance Insulet’s mission,” said Chadwick said in a news release today. “I am confident in the team and the company’s continued momentum.”
Pease, a veteran of healthcare and medical technology, has served on board of directors at Insulet — one of the largest diabetes tech companies in the world — since January 2024. She also spent more than two decades at Johnson & Johnson, like McEvoy, who joined Insulet as CEO earlier this year.
Read more about Insulet and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
“Flavia is a highly accomplished business leader with world-class healthcare and MedTech expertise,” said McEvoy. “Her extensive leadership experience in complex global organizations, proven ability to drive financial performance through disciplined execution of the company’s strategy, and track record of value creation for all stakeholders make her the ideal CFO to help guide Insulet’s next phase of patient-centric growth. Her contributions as a member of the board have already been instrumental to our strong performance and will enable a seamless transition.”
This marks the latest executive change at Insulet following McEvoy’s appointment in May. In August, the company announced promotion of Eric Benjamin to the role of chief operating officer (COO), promoting him from his chief product & consumer experience officer (CPXO). The company also appointed Manoj Raghunandanan as chief growth officer at the same time. A week later, the company appointed Amit Guliani as its next chief technology officer as well.
Alongside this announcement, Insulet said it expects to exceed its previously issued third-quarter revenue guidance. It cited strong new customer starts in both U.S. and international markets.
More about new Insulet CFO Flavia Pease
Before Charles River, Pease spent more than 20 years across the Medical Devices and Pharmaceutical segments at J&J. During her time at the medtech giant, she served as VP and group CFO of J&J’s global Medical Devices business. There, she oversaw financial operations for the company’s $27 billion global portfolio. She also served as VP of finance for Janssen North America, J&J’s largest business unit.
Other roles at J&J over 23 years included time spent with the LifeScan business, as well as VP of the Enterprise Program Management Office and VP of Finance for Janssen Supply Chain. Pease also held positions with SC Johnson and in investment banking in Brazil.
Insulet said Pease has a strong record of scaling businesses, leading global operations and driving growth in complex healthcare markets. As a member of the company’s board and audit committee, Insulet says she brings a deep understanding of its strategy, operations and financials. In connection with her appointment, Pease plans to resign from the board upon transitioning to the CFO post.
“I am thrilled to join this talented leadership team as CFO and to continue serving this outstanding Company,” said Ms. Pease. “Insulet’s commitment to improving the lives of people with diabetes is deeply inspiring, and I look forward to partnering with Ashley, the Board, and the Insulet team to build on the Company’s strong foundation, accelerate growth, and deliver lasting value for customers and shareholders.”
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang said Pease is “well-suited for the role given her closeness to the company as well as her experience in the medtech space.”
